Sorafenib, a Dual Raf Kinase/Vascular Endothelial Growth Factor Receptor Inhibitor Has Significant Anti-Myeloma Activity and Synergizes With Common Anti-Myeloma Drugs

Oncogene - United Kingdom
doi 10.1038/onc.2009.403
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients With Refractory Multiple Myeloma

Clinical Cancer Research
Cancer ResearchOncology
2004English

Anti-Vascular Endothelial Growth Factor for Neovascular Glaucoma

Cochrane Database of Systematic Reviews
2020English

The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis

Cancer Research
Cancer ResearchOncology
2008English

Anti-Myeloma Activity of MELK Inhibitor OTS167: Effects on Drug-Resistant Myeloma Cells and Putative Myeloma Stem Cell Replenishment of Malignant Plasma Cells

Blood Cancer Journal
OncologyHematology
2016English

Ten Years of Anti-Vascular Endothelial Growth Factor Therapy

Nature Reviews Drug Discovery
MedicineDrug DiscoveryPharmacology
2016English

Anti-Vascular Endothelial Growth Factor for Proliferative Diabetic Retinopathy

2010English

Vascular Endothelial Growth Factor Receptor 3 Is a Novel Marker Differing CD138-positive and CD138-negative Multiple Myeloma Cells

British Journal of Haematology
Hematology
2017English

A Recombinant Mutant Vascular Endothelial Growth Factor-C That Has Lost Vascular Endothelial Growth Factor Receptor-2 Binding, Activation, and Vascular Permeability Activities

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
1998English

Inhibition of Chronic and Acute Skin Inflammation by Treatment With a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor

American Journal of Pathology
Forensic MedicinePathology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy